Clinical Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mocellin, S.
Right arrow Articles by Nitti, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mocellin, S.
Right arrow Articles by Nitti, D.
Clinical Cancer Research Vol. 10, 6879-6886, October 15, 2004
© 2004 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity

Simone Mocellin1, Maurizio Provenzano2, Carlo Riccardo Rossi1, Pierluigi Pilati1, Romano Scalerta1, Mario Lise1 and Donato Nitti1

1 Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy; and 2 Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: The cascade of molecular events leading to tumor necrosis factor (TNF)-mediated tumor regression is still incompletely elucidated. We investigated the role of endothelial nitric oxide synthase in determining the tumor-selective activity of TNF.

Experimental Design: Using quantitative real-time PCR, endothelial nitric oxide synthase gene levels were measured in melanoma metastases of the skin and normal skin biopsies obtained from 12 patients before undergoing TNF-based therapy. In vitro, the ability of melanoma cells supernatant to affect endothelial nitric oxide synthase transcription by endothelial cells and the influence of nitric oxide synthase inhibition on TNF cytotoxicity toward endothelial cells was evaluated.

Results: Endothelial nitric oxide synthase transcript abundance resulted significantly greater in tumor samples rather than in normal skin samples and in patients showing complete response to TNF-based treatment rather than in those showing partial/minimal response. In vitro, melanoma cells’ supernatant induced endothelial nitric oxide synthase gene expression by endothelial cells. Nitric oxide synthase inhibition slowed endothelial cells proliferation and, if induced before TNF administration, decreased the cytokine-mediated cytotoxicity on endothelial cells.

Conclusions: Taken together, these findings support the hypothesis that high expression of endothelial nitric oxide synthase in the tumor microenvironment might increase or be a marker for endothelial cells sensitivity to TNF. These observations may have important prognostic and/or therapeutic implications in the clinical setting.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Tumor necrosis factor (TNF, formerly known as TNF-{alpha}) was originally characterized as an antitumor protein causing necrosis of methylcholanthrene-induced sarcomas in animal models (1) . Combined with other cytotoxic agents (e.g., doxorubicin, melphalan), TNF is currently used to treat patients affected with locally advanced soft tissue sarcoma and melanoma of the extremities, as well as unresectable liver tumors (2, 3, 4) . Several mechanisms underlying the anticancer properties of TNF have been proposed. On susceptible tumor cells, TNF exerts a direct cytotoxic effect mediated by the apoptosis pathway (5 , 6) . Moreover, in animal models, TNF stimulates the antitumor activity of innate immunity (7 , 8) and increases tumor concentrations of coadministered antineoplastic drugs (9 , 10) . However, most investigators currently believe that the main mechanism responsible for the antitumor activity of TNF is the damage of tumor vessels (11, 12, 13) , which in turn is responsible for an ischemic insult to malignant cells. TNF can directly cause endothelium apoptosis after the engagement with type I TNF receptor (14) , supposedly through a reduced activation of integrin-{alpha}Vß3 (15) . The apoptotic pathway driven by TNF is known quite in detail and involves the cascade of caspases activation (16 , 17) . However, caspase-independent cell death is caused by this cytokine as well (18 , 19) . A complex relationship exists between TNF-induced cell cytotoxicity and nitric oxide, a gaseous messenger involved in numerous biological processes and mainly produced by two nitric oxide synthase isoenzymes. Although the inducible nitric oxide synthase is expressed by different cell types (e.g., macrophages, endothelial cells, tumor cells) under certain circumstances, endothelial nitric oxide synthase is selectively transcribed by endothelial cells (20 , 21) . Although nitric oxide can contribute to later stages of TNF-induced apoptosis (22, 23, 24) , low levels of nitric oxide can inhibit central mediators of the apoptotic process such as caspases (25, 26, 27) . On the other side, some investigators have recently reported that nitric oxide production after the activation of TNF receptors could mediate a built-in negative feedback signal, with which the cytokine would control its own apoptotic program (28) .

Despite the large body of experimental and clinical data regarding the antineoplastic effect of TNF, the cascade of molecular events leading to the selective activity of this cytokine against the tumor tissue (as compared with normal tissues such as skin) has not yet been characterized.

In the present study, we investigated on the potential role of nitric oxide synthase in determining the sensitivity of tumor tissue to TNF cytotoxic effects.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
In vivo Study.
Skin melanoma metastases (n = 12) and normal skin biopsies (n = 12) were obtained from 12 patients before they underwent TNF-based isolated limb perfusion (29) , according to a protocol approved by the local ethics committee. Fully informed consent was obtained from each patient participating in this study. Before entering this study, no patient had been treated with biochemotherapy or radiation therapy.

Using quantitative real-time PCR, endothelial nitric oxide synthase and inducible nitric oxide synthase transcriptional levels expressed by tumor specimens were compared with those found in normal skin biopsies.

To document vessel destruction after TNF-based treatment, pre- and posttreatment tumor and normal skin samples were also used for the immunohistochemical evaluation of CD31 protein expression. The immunohistochemical staining was performed using CD31-specific monoclonal antibodies (Dako, Copenhagen, Denmark). Immunoperoxidase staining was performed using an Avidin-Biotin kit (Vector Laboratories, Burlingame, CA). The chromogen consisted of 3,3'-diaminobenzidine tetrachloride and counterstained with Mayer’s hematoxylin. CD31 expression was assessed by image analysis as performed by the Zeiss-Cires workstation (Zeiss, Jena, Germany). Slides were viewed through an Axioskop microscope with a x40/0.75 objective (Zeiss). Images were captured by a couple-charged device color videocamera and analyzed with a 66-MHz personal computer and digitized by a frame grabber (Kontron, Eching, Germany). The number of nuclei identified by image analysis on the basis of hematoxylin counterstaining represented the total number of cells. CD31 expression measured in 10 randomly selected x40 fields was expressed as the mean percentage of positive cells.

In vitro Study.
To dissect the results of the in vivo study, we assessed whether the supernatant obtained from the culture of different cell types potentially present in the tumor microenvironment [i.e., melanoma cells, fibroblasts and peripheral blood mononuclear cells (PBMCs)] could affect endothelial nitric oxide synthase gene expression by human umbilical vein endothelial cells (HUVECs). To this aim, 2-day-old supernatant from adherent cells (grown to 75% confluence) or from PBMCs (5 x 105 cells/mL) was used to condition HUVECs for 4 hours. Furthermore, the effect of nitric oxide synthase inhibition on the sensitivity of endothelial cells to TNF-induced cytotoxicity was evaluated. In particular, the nitric oxide synthase inhibitor N-omega-nitro-L-arginine methyl ester [L-NAME (500 µmol/L); Sigma, St. Louis, MO] was added both before and at the same time of TNF administration to assess the influence of nitric oxide before and after the cytokine interaction with its receptor. D-NAME (500 µmol/L; Sigma), the inactive enantiomer of L-NAME, was used as a control.

Cell Cultures.
Second passage HUVECs (Clonetics/BioWhittaker, Walkersville, MD) were used for most experiments. These cells were cultured in endothelium growth medium-1 according to Clonetics instructions. In some experiments (nitric oxide synthase expression and TNF-induced cytotoxicity on endothelial cells), the supernatant obtained from the culture of three melanoma cell lines [i.e., SK23, Mel-888, and Mel-624, kindly provided by Francesca M. Marincola (NIH, Bethesda, MD)], fibroblasts, or PBMCs was used to condition endothelial cells for 3 hours.

Three melanoma cell lines (i.e., SK23, Mel-888, and Mel-624) were grown in complete Iscove’s medium containing 10% heat-inactivated FCS (Biofluids, Rockville, MD).

For fibroblasts (CCL-210; American Type Culture Collection, Manassas, VA), the DMEM containing 10% heat-inactivated FCS was used.

PBMCs were collected before treatment from the patients enrolled in this study, pooled together, and cultured in complete RPMI medium supplemented with heat-inactivated human antibody serum (Gemini Bioproducts, Calabasas, CA).

Endothelial Cell Viability, Apoptosis, and Proliferation Assays.
HUVECs were incubated with and without recombinant human TNF (100 ng/mL; Boehringer, Ingelheim, Germany) and cycloheximide (1 µg/mL; Calbiochem, La Jolla, CA) for 6 hours. In some wells, the nitric oxide synthase inhibitor L-NAME (500 µmol/L) was added to the endothelial cell culture either 2 hours before or together with TNF addition. Cell viability was measured using the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt-based colorimetric assay (Roche Diagnostics, Indianapolis, IN), following the manufacturer’s guidelines. Briefly, 105 cells/well were seeded in 100 µL of culture medium, and then 50 µL of 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt labeling mixture were added per well and cells incubated for 6 hours at 37°C and 6.5% CO2. Finally, spectrophotometrical absorbance was measured by an ELISA reader (test wavelength of 450 nm, reference wavelength of 690 nm).

To additionally characterize the effect of TNF on HUVECs treated with nitric oxide synthase inhibitor, we measured the activation of caspase-3, a central mediator of TNF-{alpha}–driven caspase-dependent apoptosis, by detection of the chromophore p-nitroanilide (pNA) after cleavage from the labeled substrate DEVD-pNA (ApoAlert Caspase-3 Colorimetric Assay; Clontech, Palo Alto, CA), following the manufacturer’s instructions. Briefly, HUVECs (5 x 106) were treated for 6 hours with TNF ± L-NAME (500 µmol/L), the nitric oxide synthase inhibitor being added 2 hours before or at the same time of the cytokine addition. Then, cells were washed with PBS, resuspended in ice-cold lysis buffer, and incubated on ice for 10 minutes. Cell lysate supernatants were prepared after centrifugation (10,000 x g for 3 minutes). The supernatants were incubated with caspase-3 substrate DEVD-pNA for 1 h at 37°C, and then absorbance (corresponding to substrate cleavage and thus caspase activity) was measured at 405 nm.

To assess the effect of nitric oxide synthase inhibition on endothelial cell proliferation rate, HUVECs (104 cells/well in 100 µL of culture medium) were grown under basal conditions, as well as in the presence of L-NAME (500 µmol/L). The above mentioned 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt-based colorimetric assay (Roche Diagnostics) was used to quantify cell proliferation.

Nitric Oxide Synthase Activity Assay.
Nitric oxide synthase activity was assayed in intact endothelial cells by measuring the conversion of L-[3H]arginine (Amersham Pharmacia Biotech, Inc., Piscataway, NJ) into L-[3H]citrulline. Endothelial cell monolayers were washed and then incubated for 20 minutes at 37°C in a reaction buffer containing 145 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgSO4, 10 mmol/L glucose, 1 mmol/L CaCl2, and 10 mmol/L HEPES (pH 7.4), with or without L-NAME (500 µmol/L). A total of 2.5 µCi/ml L-[3H]arginine was added 5 minutes before conditioning endothelial cells with L-NAME or melanoma supernatant. Control cells (endothelial cells conditioned with the inactive enantiomer D-NAME) were run in parallel. Fifteen minutes later, the monolayers were washed with 2 mL of ice-cold PBS supplemented with L-arginine (5 mmol/L) and EDTA (4 mmol/L). A total of 0.5 mL of 100% cold etomidate was added to the dishes and left to evaporate before a final addition of 2 mL of 20 mmol/L HEPES. Separation of L-[3H]citrulline from L-[3H]arginine was obtained by Dowex 50 x 8 to 400 chromatography (Sigma; ref. 30 ).

cDNA Synthesis and Quantitative Real-Time PCR.
After RNA extraction using RNeasy Mini kits (Qiagen, Santa Clarita, CA), 1 µg of total RNA was reverse transcribed into cDNA using 1 µL of random hexamers, 5 µL of first-strand buffer, 2 µL of 0.1 mol/L DTT, 2 µL of magnesium sulfate, 1 µL of 10 mmol/L deoxynucleotide triphosphate, and 1 µL of Superscript II. The reaction mixture was heated to 65°C for 10 minutes before adding Superscript II; synthesis was then continued with 1-hour incubation at 42°C. Levels of gene expression were assessed by quantitative real-time PCR as performed by the ABI Prism 7700 Sequence Detection System (Perkin-Elmer, Foster City, CA), as already described by us (31 , 32) .

To validate the amount and quality of source RNA, transcript levels of two housekeeping genes (i.e., ß-actin and CD31) were also measured. As endothelial nitric oxide synthase is selectively produced by endothelial cells, we could use it as an endothelial cell-specific housekeeping gene (i.e., CD31; refs. 33 , 34 ). Instead, we used ß-actin to analyze inducible nitric oxide synthase mRNA abundance because this isoenzyme can be produced by different cell types (e.g., melanoma cells, endothelial cells, and macrophages). For each sample, endothelial nitric oxide synthase and inducible nitric oxide synthase transcript values were corrected by the copies of the respective housekeeping gene (CD31 and ß-actin, respectively) to obtain normalized values independent of variations in the starting material. In particular, endothelial nitric oxide synthase gene levels were reported as the number of gene copies per 1 x 105 copies of CD31. Probes and primers were the following: endothelial nitric oxide synthase (fwd) 5'-CCGGGACTTCATCAACCAGTAC-3', (rev) 5'-TTGAAGCCGCTGTTCGTG-3', (probe) 5'-TCCATTAAGAGGAGCGGCTCCCAGG-3'; inducible nitric oxide synthase (fwd) 5'-GGGAGGATCCAGTGGTCCA-3', (rev) 5'-AAACATTTCCCGGGCAGTG-3', (probe) 5'-TGCAGGTCTTCGATGCCCGCA-3'; ß-actin (fwd) 5'-GGCACCCAGCACAATGAAG-3', (rev) 5'-GCCGATCCACACGGAGTACT-3', (probe) 5'-TCAAGATCATTGCTCCTCCTGAGAGCGC-3'; and CD31 (fwd) 5'-GTCCTGCTGACCCTTCTGCTCT-3', (rev) 5'-TGTACTTCTCGGACGGCCT-3', (probe) 5'-CAAGCCTTGAGGGTCAAGAAAACTCT-3'. They were designed to span intron-exon junctions (to avoid amplification of genomic DNA) and to obtain amplicons < 150 bp in length, thus enhancing PCR efficiency. TaqMan probes were labeled at the 5'-end with the reporter dye 6-carboxyfluorescein (emission {lambda}max = 518 nm) and at the 3'-end with the quencher dye 6-carboxytetramethylrhodamine (emission {lambda}max = 582 nm). Reactions were conducted with 1 µL of cDNA in a 25-µL final volume mixture containing primers and probe at optimized concentrations (400 and 200 nmol/L, respectively) and 1x TaqMan Master Mix (Perkin-Elmer). Thermal cycler parameters included 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles involving denaturation at 95°C for 15 seconds and annealing/extension at 60°C.

Statistical Analysis.
In vitro experiments were repeated four times. All experiments were performed in triplicate and the results were expressed as mean values ± SD.

The unpaired two tails Student’s t test was used to compare gene expression between tumor samples. The paired version of the same test was performed to compare gene levels of tumor samples with those observed in skin biopsies, as well as to analyze the results of the in vitro study. P values < 0.05 were considered significant.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
In vivo Study.
Tumor response was evaluated 1 month after treatment by physical examination. Complete (disappearance of all clinically detectable tumor nodules), partial (regression of tumor burden > 50%), and minimal (25 to 50% regression of tumor burden) tumor responses were observed in 6 (50%), 4 (33%), and 2 (17%) patient, respectively. The overall (complete + partial) tumor response rate was 83% (10 of 12), which is in line with the results reported worldwide (2) .

Skin toxicity was recorded in five patients (42%) and was limited to mild erythema [grade 1 according to the Wieberdink scale for the evaluation of locoregional toxicity after isolated limb perfusion (35) ].

Image analysis data showed vessel destruction within tumor samples after TNF-based treatment: the mean percentage of CD31-positive cells was significantly lower 3 days after treatment rather than in those obtained before therapy (2 ± 0.4 and 11 ± 1.9%, respectively, P = 0.015). No such difference was found in normal skin samples (mean percentage of CD31-positive cells: 9 ± 2.1 and 12 ± 1.1%, respectively, P = 0.52).

Endothelial nitric oxide synthase gene expression was different in tumor as compared with normal skin biopsies (Fig. 1Citation , top panel). Its transcriptional levels in skin melanoma metastases were significantly higher than those found in normal skin (endothelial nitric oxide synthase mean copy number = 397 ± 196 and 118 ± 44 per 105 copies of CD31, respectively, P = 0.005). In addition, endothelial nitric oxide synthase mRNA abundance was higher in complete responders rather than in partial/minimal responders (endothelial nitric oxide synthase mean copy number = 548 ± 192 and 236 ± 90 per 105 copies of CD31, respectively, P = 0.014; Fig. 1Citation , bottom panel).



View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Top panel. Transcriptional levels of endothelial (eNOS) and inducible (iNOS) nitric oxide synthase and CD31 in tumor and normal skin biopsies obtained from 12 patients before TNF-based treatment. Gene levels were measured by quantitative real-time PCR and normalized by either a nonspecific housekeeping gene (ß-actin) or an endothelial cell-specific reference gene (CD31). eNOS expression was found higher in tumor rather than in skin samples using both housekeeping genes (mean copy number of eNOS = 128 ± 54 and 56 ± 22 per 106 copies of ß-actin, respectively, P = 0.009; and 397 ± 196 and 118 ± 44 per 105 copies of CD31, respectively; P = 0.005). No significant difference was observed in CD31 or iNOS mRNA levels between the two study groups. Bottom panel. Transcriptional levels of eNOS and iNOS in tumor (skin melanoma metastases) biopsies obtained from 12 patients before treatment (TNF-based isolated limb perfusion). Gene expression observed in complete responders (CRs) was compared with that in partial and minimal responders (PRs + MRs). Target (i.e., eNOS and iNOS) and housekeeping (i.e., CD31 and ß-actin, respectively) gene copies were measured by quantitative real-time PCR. For each sample, eNOS and iNOS transcript values were corrected by the copies of the respective housekeeping gene (CD31 and ß-actin, respectively) to obtain normalized values independent of variations in the starting material. NOS gene levels were reported as the number of gene copies per 1 ± 105 copies of the housekeeping gene. eNOS expression was found higher in CRs rather than in PRs + MRs (eNOS mean copy number = 548 ± 192 and 236 ± 90 per 105 copies of CD31, respectively; P = 0.014). No significant difference was observed in iNOS mRNA levels between the two study groups.

 
No differences in inducible nitric oxide synthase transcriptional levels were found between normal and tumor tissues or between complete responders and partial/minimal responders.

CD31 and Nitric Oxide Synthase In vitro Gene Expression.
To assess whether CD31 could be used as an endothelial cell-specific housekeeping gene, CD31 mRNA expression by endothelial cells (HUVECs) was measured under different conditions (supernatant from melanoma cells/fibroblasts/PBMCs). As shown in Fig. 2Citation , top panel, CD31 mRNA levels were uniformly highly expressed by HUVECs, no matter what culture conditions were applied. No significant mRNA levels of CD31 were expressed by other cell types such as fibroblasts, PBMCs, and melanoma cell lines (data not shown).



View larger version (39K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Top panel. CD31 mRNA expression by endothelial cells (HUVECs) measured under different conditions (basal medium or supernatant from melanoma cells/fibroblasts/PBMCs) using quantitative real-time PCR. CD31 mRNA levels were uniformly highly expressed by HUVECs no matter what culture conditions were applied. This finding, together with a linear relationship between gene copy number and endothelial cell density (data not shown), supported the use of CD31 as a housekeeping gene. Bottom panel. Endothelial (eNOS) and inducible (iNOS) nitric oxide synthase mRNA expression by HUVECs under different culture conditions. eNOS transcriptional abundance was significantly higher in the presence of the supernatants collected from three melanoma cell lines as compared with basal conditions (i.e., endothelial cell basal medium; P = 0.001, 0.003, 0.017). No such effect was observed when HUVECs were grown with the supernatant obtained from fibroblasts or PBMC cell cultures. No variations in iNOS mRNA expression by HUVECs were observed under any of the above mentioned culture conditions. The data represent the means ± SD from four separate experiments performed in triplicate.

 
Endothelial and inducible nitric oxide synthase mRNA expression by endothelial cells and other cell types potentially present in the tumor microenvironment is illustrated in Fig. 3Citation .



View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Endothelial (eNOS) and inducible (iNOS) nitric oxide synthase in vitro gene expression in different cell types (endothelial cells, ECs; leukocytes, PBMCs; fibroblasts, fibro; melanoma cell lines, SK-23/Mel-888/Mel-624) potentially present in the tumor microenvironment. mRNA levels were measured by quantitative real-time PCR. The data, which are expressed as the target gene copy number/105 housekeeping gene copies, are the means ± SD from four separate experiments performed in triplicate.

 
Considering endothelial cells, endothelial nitric oxide synthase transcriptional levels were significantly increased in the presence of the supernatants collected from three melanoma cell lines as compared with basal conditions (i.e., endothelial cell basal medium; P = 0.001, 0.003, 0.017; Fig. 2Citation , bottom panel). No such effect was observed when HUVECs were grown with the supernatant obtained from fibroblasts or PBMC cell cultures.

No variations in inducible nitric oxide synthase mRNA expression by HUVECs were observed under any of the above mentioned culture conditions.

Endothelial Cell Viability, Apoptosis, and Proliferation Assays.
As demonstrated by the cell viability and apoptosis assays, inhibition of nitric oxide synthase activity with L-NAME significantly decreased TNF-mediated cytotoxicity against endothelial cells when the nitric oxide synthase inhibitor was added 2 hours before TNF addition (Fig. 4Citation ; at time 6 hours, t test, P = 0.01 and 0.02, respectively). By contrast, nitric oxide synthase inhibition at the same time of TNF administration had no significant effect on the cytotoxic effect.



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. In vitro modulation of TNF cytotoxicity on endothelial cells using an inhibitor of nitric oxide synthases (L-NAME). When L-NAME was added to the culture medium before TNF (L-NAME/TNF), cytotoxicity was significantly reduced, as showed by both the apoptosis assay (caspase-3 activation colorimetric assay, top panel) and the viability assay (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt colorimetric assay, bottom panel) assay (at time 6 hours, t test, P = 0.01 and 0.02, respectively). In particular, the difference of the administration of L-NAME together with the cytokine (TNF + L-NAME) had no significant effect on TNF-mediated cytotoxicity. Controls included L-NAME alone and its inactive enantiomer, D-NAME. The data represent the means ± SD from four separate experiments performed in triplicate. *, D-NAME; {blacksquare}, TNF; •, L-NAME/TNF; {blacktriangleup}, TNF+L-NAME; {circ}, L-NAME.

 
The proliferation of endothelial cells was significantly diminished by adding the nitric oxide synthase inhibitor to the culture medium (Fig. 5Citation ; at time 6 days, t test, P = 0.004).



View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Endothelial cell proliferation and nitric oxide synthase inhibition. Human umbilical vein endothelial cells were cultured for 6 days under normal conditions (none) and in the presence of nitric oxide synthase inhibitor (L-NAME). Cell proliferation was measured by performing the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt colorimetric assay at 2-day intervals. Inhibition of nitric oxide production significantly reduced the rate of cell growth (at time 6 days, t test, P = 0.004). The data represent the means ± SD from four separate experiments performed in triplicate.

 
Nitric Oxide Synthase Activity Assay.
The correlation between endothelial nitric oxide synthase gene expression and enzymatic activity under different experimental conditions is illustrated in Table 1Citation .


View this table:
[in this window]
[in a new window]

  		Table 1 eNOS gene expression and NOS enzymatic activity in ECs treated with NOS inhibitor L-NAME, its inactive enantiomer D-NAME (negative control), and in the presence of melanoma supernatant ± L-NAME

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The selectivity of TNF cytotoxic effect for tumor as compared with normal tissues is well known to clinicians (2, 3, 4) . The identification of the mechanisms underlying this tumor-specific activity of TNF could be of paramount importance to open new avenues of research in the field of molecularly targeted anticancer therapy.

In the in vivo study, we found that endothelial nitric oxide synthase mRNA levels were significantly higher in tumor rather than in skin samples (Fig. 1)Citation . As endothelial nitric oxide synthase is selectively expressed by endothelial cells (Fig. 3)Citation , it can be postulated that only endothelial cells could be responsible for this differential gene display. We ruled out that this difference was due to a different number of endothelial cells present in the tumor/skin specimens by normalizing endothelial nitric oxide synthase transcriptional levels by the mRNA levels of an endothelial-specific housekeeping gene (i.e., CD31; refs. 33 , 34 ), according to a method already validated (31 , 36) . Using a nonspecific housekeeping gene such as ß-actin, differences in endothelial nitric oxide synthase expression between tumor and normal tissue were still significant. This was supported by the fact that no difference in endothelial cell density was found between diseased and normal tissue samples, as determined by the ratio CD31/ß-actin gene expression (Fig. 1)Citation . However, because differences in vessel density cannot be ruled out a priori, we chose to normalize endothelial nitric oxide synthase mRNA levels by CD31 to minimize the risk of false findings due to dissimilar degree of tissue vascularization.

Tumor endothelial nitric oxide synthase levels resulted higher in complete rather than in partial/minimal responders (Fig. 1)Citation . Considering the minimal skin toxicity and the different tumor responses (complete versus partial/minimal) recorded after the TNF-based treatment, these in vivo findings led us to hypothesize that endothelial nitric oxide synthase overexpression might underlie both the tumor specific activity of TNF and the variation of tumor response observed in the clinical setting. In vitro experiments did support this hypothesis. We first verified that endothelial nitric oxide synthase expression by endothelial cells was quite constant under different experimental conditions, except when melanoma supernatant was used (Fig. 2)Citation . In this case, endothelial nitric oxide synthase transcription significantly increased, showing that—just like the so-called inducible nitric oxide synthase—the endothelial isoenzyme is also inducible. A good correlation between endothelial nitric oxide synthase gene expression and nitric oxide synthase enzymatic activity (Table 1)Citation strengthened these results. By demonstrating that melanoma cells can up-regulate endothelial nitric oxide synthase expression by endothelial cells, in vitro data supported the above discussed in vivo findings (i.e., different endothelial nitric oxide synthase expression by tumor as compared with skin samples).

Nitric oxide is believed to play a significant role in angiogenesis (as supported by the inhibition of endothelial cell proliferation by nitric oxide synthase inhibition; see Fig. 5Citation ) and immune suppression during tumor progression (37, 38, 39, 40, 41, 42, 43, 44) . From a teleological viewpoint, endothelial nitric oxide synthase overexpression by endothelial cells might be a mechanism of malignant cells to promote the angiogenic process and inhibit the immunologic surveillance. Some investigators have postulated that malignant cells themselves produce nitric oxide by increasing their own expression of inducible nitric oxide synthase (45, 46, 47, 48) . Others have reported that stromal cells (e.g., tumor-infiltrating macrophages) might be responsible for the production of nitric oxide and consequently favor tumor progression-related processes such as neoangiogenesis (49) . In the present study, we found that melanoma cell lines did not overexpress inducible nitric oxide synthase as compared with normal cell types (Fig. 3)Citation , whereas their supernatant did cause endothelial cells to transcribe endothelial nitric oxide synthase by a not yet identified soluble factor. A proteomics-based study (50) aimed at identifying this/these molecule(s) is currently under way in our laboratory.

Inhibition of nitric oxide synthase activity was accompanied in vitro by a reduction of TNF-driven cytotoxicity of endothelial cells when nitric oxide synthase suppression was achieved before TNF addition to the culture medium. This effect most likely depended on the inhibition of the endothelial isoenzyme because no significant levels of inducible nitric oxide synthase were found to be expressed by HUVECs (Fig. 3)Citation . These data indicate that high nitric oxide synthase expression (as obtained conditioning endothelial cells with melanoma cell line supernatant) favors the cytotoxicity of TNF toward human endothelial cells, thus providing a potential link between clinical tumor response to TNF-based treatment and endothelial nitric oxide synthase expression levels in tumor samples (Fig. 1)Citation . Endothelial cells are relatively resistant to the cytotoxic effect of TNF, as demonstrated by the need of coadministering cycloheximide to kill endothelial cells in vitro (51 , 52) ; however, high pretreatment levels of nitric oxide might lower the threshold of endothelial cell sensitivity to the cytokine, as supported by the inhibition of TNF cytotoxicity obtained with nitric oxide synthase inhibitors (Fig. 4)Citation . In particular, it might be hypothesized that the production of cytotoxic-mixed free radicals (e.g.,–OONO) is favored by high levels of nitric oxide in the presence of reactive oxygen species, whose production is notoriously increased by TNF and involved in cytokine-induced cytotoxicity (53) . On the other hand, caspase-dependent apoptotic death can be inhibited by nitric oxide (25, 26, 27) , which might theoretically reduce TNF-mediated cytotoxicity toward endothelial cells. However, some investigators have reported that caspase inhibition can favor reactive oxygen species-mediated cytotoxicity (54 , 55) , which in turn might favor TNF cytotoxic activity. Finally, in our model, suppression of nitric oxide synthase activity (and thus nitric oxide production) soon after the interaction between the cytokine and its receptor did not affect TNF cytotoxicity, which confirms the complex and still unclear relationship between nitric oxide and TNF effects and calls for additional studies aimed at elucidating the molecular basis of their interaction.

Another hypothesis might be formulated to help interpret our findings. Nitric oxide has been reported to mediate vascular endothelial growth factor-proliferative effects on endothelial cells (37) , and melanoma cells are known to produce vascular endothelial growth factor (56 , 57) . Furthermore, we found that in the presence of melanoma supernatant, endothelial cells express more endothelial nitric oxide synthase, which correlates with a higher rate of cycling endothelial cells (Fig. 6)Citation . Accordingly, the overexpression of this gene in tumor tissue samples (as compared with normal skin samples) might represent just a marker of endothelial cell cycle status. If high-endothelial nitric oxide synthase/cycling (rather than low endothelial nitric oxide synthase/resting) endothelial cells are more sensitive to TNF activity, the blockage of endothelial nitric oxide synthase-proliferative effect (by L-NAME) before TNF administration likely enables us to appreciate the inhibitory effect of L-NAME on TNF cytotoxicity. By contrast, in the case of synchronous administration of L-NAME and TNF, the cytokine cytotoxic effects might occur before cell cycle is shut down, and endothelial cells become resistant to TNF.



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Effects of melanoma supernatant on endothelial cell cycle as demonstrated by flow cytometry analysis. Endothelial cells were stained with propidium iodide (50 µg/mL) and fluorescence measured on a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA) using the CellQuest software for data acquisition and analysis. In the presence of melanoma supernatant (right panel), the proportion of cycling endothelial cells (G2-M fraction) was greater than that observed under control conditions (endothelial cells cultured without melanoma supernatant, left panel).

 
Overall, this study suggests that the induction of endothelial nitric oxide synthase expression by melanoma, which might provide the tumor with a survival advantage by promoting angiogenesis, increases the sensibility of endothelial cells to TNF, providing a new hypothesis to explain both the tumor selective cytotoxic activity of this cytokine and the variable tumor responses observed in the clinical setting. According to these considerations, the measurement of endothelial nitric oxide synthase gene expression in pretreatment tumor samples might be used as a prognostic factor for tumor response and guide physicians during the selection of patients candidate for TNF-based anticancer therapy. Moreover, the antineoplastic activity of this cytokine might be augmented by adding nitric oxide synthase inhibitors to the drug regimen. In fact, because nitric oxide synthase inhibitors do not inhibit TNF-driven cytotoxicity when they are added together with this cytokine, these agents could be coadministered to add an antiproliferative effect to the cytotoxic activity of TNF. This way, an improved tumor response rate is expected, as recently observed in an animal model of soft tissue sarcoma (58) .


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Simone Mocellin, Università di Padova, Dipartimento di Scienze Oncologiche e Chirurgiche, Sezione di Clinica Chirurgica, Policlinico Universitario (6° piano), Via Giustiniani, 2, 35128 Padova, Italy. Phone: 39-049-8212055; Fax: 39-049-651891; E-mail: mocellins{at}hotmail.com

Received 4/22/04; revised 7/12/04; accepted 7/15/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.[Abstract/Free Full Text]
  2. Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002;29:400-9.[CrossRef][Medline]
  3. Rossi CR, Mocellin S, Pilati P, Foletto M, Nitti D, Lise M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends. J Immunother 2003;26:291-300.
  4. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.[Abstract/Free Full Text]
  5. Duerksen-Hughes PJ, Day DB, Laster SM, Zachariades NA, Aquino L, Gooding LR. Both tumor necrosis factor and nitric oxide participate in lysis of simian virus 40-transformed cells by activated macrophages. J Immunol 1992;149:2114-22.[Abstract]
  6. Kwak JY, Han MK, Choi KS, et al Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol 2000;203:84-94.[CrossRef][Medline]
  7. Lotzova E, Savary CA. Human natural killer cell development from bone marrow progenitors: analysis of phenotype, cytotoxicity and growth. Nat Immun 1993;12:209-17.[Medline]
  8. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002;168:1831-9.[Abstract/Free Full Text]
  9. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.[CrossRef][Medline]
  10. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha–based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82:973-80.[CrossRef][Medline]
  11. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000;156:1171-6.[Abstract/Free Full Text]
  12. Gnant MF, Berger AC, Huang J, et al Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res 1999;59:4668-74.[Abstract/Free Full Text]
  13. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998;10:573-80.[CrossRef][Medline]
  14. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol 2001;70:317-25.[CrossRef][Medline]
  15. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14.[CrossRef][Medline]
  16. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.[CrossRef][Medline]
  17. Aggarwal B. Signaling pathways of the TNF superfamily: a double edged sword. Nat Rev Immunol 2003;3:745-56.[CrossRef][Medline]
  18. Maianski NA, Roos D, Kuijpers TW. Tumor necrosis factor alpha induces a caspase-independent death pathway in human neutrophils. Blood 2003;101:1987-95.[Abstract/Free Full Text]
  19. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589-98.[CrossRef][Medline]
  20. Dimmeler S, Zeiher AM. Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. Nitric Oxide 1997;1:275-81.[CrossRef][Medline]
  21. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 2002;8:177-200.[CrossRef][Medline]
  22. Estrada C, Gomez C, Martin C, Moncada S, Gonzalez C. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem Biophys Res Commun 1992;186:475-82.[CrossRef][Medline]
  23. Maciejewski JP, Selleri C, Sato T, et al Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Investig 1995;96:1085-92.
  24. Binder C, Schulz M, Hiddemann W, Oellerich M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha–induced apoptosis in MCF-7 and other epithelial tumor cells. Lab Investig 1999;79:1703-12.[Medline]
  25. De Nadai C, Sestili P, Cantoni O, et al Nitric oxide inhibits tumor necrosis factor-alpha–induced apoptosis by reducing the generation of ceramide. Proc Natl Acad Sci USA 2000;97:5480-5.[Abstract/Free Full Text]
  26. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3–like activity via two distinct mechanisms. J Biol Chem 1997;272:31138-48.[Abstract/Free Full Text]
  27. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta–converting enzyme (ICE)-like and cysteine protease protein (CPP)-32–like proteases. J Exp Med 1997;185:601-7.[Abstract/Free Full Text]
  28. Bulotta S, Barsacchi R, Rotiroti D, Borgese N, Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J Biol Chem 2001;276:6529-36.[Abstract/Free Full Text]
  29. Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004;11:173-7.[Abstract/Free Full Text]
  30. Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 1989;86:9030-3.[Abstract/Free Full Text]
  31. Mocellin S, Rossi C, Pilati P, Nitti D, Marincola F. Quantitative real time PCR: a powerful ally in cancer research. Trends Mol Med 2003;9:189-195.[CrossRef][Medline]
  32. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer 2003;107:317-22.[CrossRef][Medline]
  33. de la Taille A, Katz AE, Bagiella E, et al Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. Am J Clin Pathol 2000;113:555-62.[Abstract/Free Full Text]
  34. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000;60:3088-95.[Abstract/Free Full Text]
  35. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.[CrossRef][Medline]
  36. Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J Immunol Methods 2003;280:1-11.[CrossRef][Medline]
  37. Ziche M, Morbidelli L, Choudhuri R, et al Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Investig 1997;99:2625-34.[Medline]
  38. Moochhala S, Rajnakova A. Role of nitric oxide in cancer biology. Free Radic Res 1999;31:671-9.[CrossRef][Medline]
  39. Hegardt P, Widegren B, Sjogren HO. Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol 2000;200:116-27.[CrossRef][Medline]
  40. Kahn DA, Archer DC, Gold DP, Kelly CJ. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. J Exp Med 2001;193:1261-8.[Abstract/Free Full Text]
  41. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16.[CrossRef][Medline]
  42. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis (Lond.) 1998;19:711-21.[Abstract/Free Full Text]
  43. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 1998;17:107-18.[CrossRef][Medline]
  44. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002;12:311-20.[CrossRef][Medline]
  45. Ambs S, Merriam WG, Ogunfusika MO, et al p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998;4:1371-6.[CrossRef][Medline]
  46. Konopka TE, Barker JE, Bamford TL, Guida E, Anderson RL, Stewart AG. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001;61:3182-7.[Abstract/Free Full Text]
  47. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000;86:30-9.[CrossRef][Medline]
  48. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999;155:1381-90.[Abstract/Free Full Text]
  49. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000;6:2408-16.[Abstract/Free Full Text]
  50. Mocellin S, Riccardo Rossi C, Traldi P, Nitti D, Lise M. Molecular oncology in the post-genomic era: the challenge of proteomics. Trends Mol Med 2004;10:24-32.[CrossRef][Medline]
  51. Binder C, Binder L, Kroemker M, Schulz M, Hiddemann W. Influence of cycloheximide-mediated down-regulation of glucose transport on TNF alpha-induced apoptosis. Exp Cell Res 1997;236:223-30.[CrossRef][Medline]
  52. Slowik MR, Min W, Ardito T, Karsan A, Kashgarian M, Pober JS. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1–converting enzyme-like protease-dependent and -independent pathways. Lab Investig 1997;77:257-67.[Medline]
  53. Carretero J, Obrador E, Esteve JM, et al Tumoricidal activity of endothelial cells. Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro. J Biol Chem 2001;276:25775-82.[Abstract/Free Full Text]
  54. Vercammen D, Beyaert R, Denecker G, et al Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998;187:1477-85.[Abstract/Free Full Text]
  55. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003;4:387-93.[CrossRef][Medline]
  56. Abe K, Shoji M, Chen J, et al Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663-8.[Abstract/Free Full Text]
  57. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001;61:7282-90.[Abstract/Free Full Text]
  58. de Wilt JH, Manusama ER, van Etten B, et al Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer 2000;83:1176-82.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 The OncologistHome page
R. van Horssen, T. L. M. ten Hagen, and A. M. M. Eggermont
TNF-{alpha} in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility.
Oncologist, April 1, 2006; 11(4): 397 - 408.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mocellin, S.
Right arrow Articles by Nitti, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mocellin, S.
Right arrow Articles by Nitti, D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online